Purpose: Recent epidemiological and clinical studies have suggested the benefit of
aspirin for patients with
cancer, which inspired increasing efforts to demonstrate the anticancer ability of
aspirin and reveal the molecular mechanisms behind. Nevertheless, the anticancer activity and related mechanisms of
aspirin remain largely unknown. This study aimed to confirm this observation, and more importantly, to investigate the potential target contributed to the anticancer of
aspirin.Experimental Design: A homogeneous time-resolved fluorescence (HTRF) assay was used to examine the impact of
aspirin on
heparanase.
Streptavidin pull-down, surface plasmon resonance (SPR) assay, and molecular docking were performed to identify
heparanase as an
aspirin-
binding protein. Transwell, rat aortic rings, and chicken chorioallantoic membrane model were used to evaluate the antimetastasis and
anti-angiogenesis effects of
aspirin, and these phenotypes were tested in a B16F10 metastatic model, MDA-MB-231 metastatic model, and MDA-MB-435 xenograft model.Results: This study identified
heparanase, an oncogenic extracellular matrix
enzyme involved in
cancer metastasis and angiogenesis, as a potential target of
aspirin. We had discovered that
aspirin directly binds to Glu225 region of
heparanase and inhibits the enzymatic activity.
Aspirin impeded
tumor metastasis, angiogenesis, and growth in
heparanase-dependent manner.Conclusions: In summary, this study has illustrated
heparanase as a target of
aspirin for the first time. It provides insights for a better understanding of the mechanisms of
aspirin in anticancer effects, and offers a direction for the development of small-molecule inhibitors of
heparanase. Clin
Cancer Res; 23(20); 6267-78. ©2017 AACR.